CytoMed Therapeutics (FRA:F98) Cash-to-Debt : 20.04 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CytoMed Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 20.04.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CytoMed Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for CytoMed Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:F98' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3 Med: 0.57 Max: 20.1
Current: 20.1

During the past 4 years, CytoMed Therapeutics's highest Cash to Debt Ratio was 20.10. The lowest was 0.30. And the median was 0.57.

FRA:F98's Cash-to-Debt is ranked better than
64.01% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs FRA:F98: 20.10

CytoMed Therapeutics Cash-to-Debt Historical Data

The historical data trend for CytoMed Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CytoMed Therapeutics Cash-to-Debt Chart

CytoMed Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.30

0.77

0.37

20.04

CytoMed Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			0.77	0.44	0.37	22.09	20.04

Competitive Comparison of CytoMed Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, CytoMed Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Cash-to-Debt falls into.

CytoMed Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CytoMed Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.192	/	(0.028	+	0.281)
	=	20.04

CytoMed Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.192	/	(0.028	+	0.281)
	=	20.04

CytoMed Therapeutics (FRA:F98) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CytoMed Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (FRA:F98) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (FRA:F98) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

GDTC:USA

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

CytoMed Therapeutics (FRA:F98) Headlines

No Headlines